{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:19:05Z","timestamp":1779380345640,"version":"3.53.1"},"reference-count":20,"publisher":"AMPCo","issue":"6","license":[{"start":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T00:00:00Z","timestamp":1316390400000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Journal of Australia"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.5694\/mja11.10941","type":"journal-article","created":{"date-parts":[[2011,9,16]],"date-time":"2011-09-16T10:55:12Z","timestamp":1316170512000},"page":"318-320","source":"Crossref","is-referenced-by-count":22,"title":["Adverse events associated with 2010 CSL and other inactivated influenza vaccines"],"prefix":"10.5694","volume":"195","author":[{"given":"Heath A","family":"Kelly","sequence":"first","affiliation":[{"name":"Epidemiology Unit, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta M","family":"Skowronski","sequence":"additional","affiliation":[{"name":"BC Centre for Disease Control, Vancouver, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston","family":"Serres","sequence":"additional","affiliation":[{"name":"Institut national de sant\u00e9 publique du Qu\u00e9bec, Qu\u00e9bec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul V","family":"Effler","sequence":"additional","affiliation":[{"name":"Communicable Disease Control Directorate, WA Health, Perth, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3677","published-online":{"date-parts":[[2011,9,19]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2010-000016","article-title":"Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine","author":"Armstrong PK","year":"2011","journal-title":"BMJ Open"},{"key":"e_1_2_8_3_2","unstructured":"Australian Technical Advisory Group on Immunisation.Clinical advice for immunisation providers on resumption of the use of 2010 trivalent seasonal vaccines in children less than 5 years of age 30 July 2010.http:\/\/www.health.gov.au\/internet\/immunise\/Publishing.nsf\/content\/immunise\u2010atagi\u2010statement\u2010tiv(accessed Aug 2011)."},{"key":"e_1_2_8_4_2","volume-title":"The TGA and the USA FDA agree about problems at CSL Biotherapies","author":"Therapeutic Goods Administration","year":"2011"},{"key":"e_1_2_8_5_2","first-page":"324","volume-title":"Textbook of influenza","author":"Furminger IGS","year":"1998"},{"key":"e_1_2_8_6_2","volume-title":"Excipients in vaccines","author":"Institute for Vaccine Safety","year":"2010"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/136.5.623"},{"key":"e_1_2_8_8_2","first-page":"213","article-title":"Comparison of adverse reactions to whole\u2010virion and split\u2010virion influenza vaccines in hospital personnel","volume":"145","author":"al\u2010Mazrou A","year":"1991","journal-title":"CMAJ"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/367667"},{"key":"e_1_2_8_10_2","first-page":"1","article-title":"Supplementary statement for the 2001\u20132002 season: influenza vaccination of persons who experienced oculo\u2010respiratory syndrome following previous influenza vaccination","volume":"27","author":"National Advisory Committee on Immunization","year":"2001","journal-title":"Can Commun Dis Rep"},{"key":"e_1_2_8_11_2","first-page":"17","article-title":"Oculorespiratory syndrome","volume":"78","author":"Global Advisory Committee on Vaccine Safety","year":"2003","journal-title":"Week Epi Rec"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/378274"},{"key":"e_1_2_8_13_2","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/S0264-410X(98)00467-8","article-title":"Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study","volume":"17","author":"Splia\u2010Alegani S","year":"1999","journal-title":"Vaccine"},{"key":"e_1_2_8_14_2","unstructured":"TumovaB SchramlovaJ VitkovaE et al.Is the release control of influenza vaccine sufficient. In:Programs and abstracts of Options for the Control of Influenza III; Cairns Queensland;1996."},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)90040-8"},{"key":"e_1_2_8_16_2","unstructured":"Therapeutic Goods Administration.Overview of vaccine regulation and safety monitoring and investigation into adverse events following 2010 seasonal influenza vaccination in young children.Attachment E: TGA influenza seasonal trivalent influenza vaccine laboratory investigation program.http:\/\/www.tga.gov.au\/safety\/alerts\u2010medicine\u2010seasonal\u2010flu\u2010101008.htm#attachments(accessed Aug 2011)."},{"key":"e_1_2_8_17_2","unstructured":"Centers for Disease Control and Prevention (US).ACIP recommendation for use of CSL influenza vaccine [media statement]. 6 Aug2010.http:\/\/www.cdc.gov\/media\/pressrel\/2010\/s100806.htm(accessed Sep 2011)."},{"key":"e_1_2_8_18_2","unstructured":"Food and Drug Administration (US).Inspections compliance enforcement and criminal investigations.Warning letter to Commonwealth Serum Laboratories (CSL) Ltd. June 15 2011.http:\/\/www.fda.gov\/ICECI\/EnforcementActions\/WarningLetters\/ucm259888.htm(accessed Jul 2011)."},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-2659.2009.00108.x"},{"key":"e_1_2_8_20_2","unstructured":"Commonwealth Serum Laboratories.Influenza virus vaccine 2010\u20132011 formula (STN BL 125254\/181). Highlights of prescribing information.http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm220730.pdf(accessed Aug 2011)."},{"key":"e_1_2_8_21_2","unstructured":"ClinicalTrials.gov. A study to determine the immunogenicity and safety profile of CSL Limited's influenza virus vaccine compared to a US licensed comparator influenza virus vaccine in a pediatric population.http:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00959049(accessed Aug 2011)."}],"container-title":["Medical Journal of Australia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.5694\/mja11.10941","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.5694\/mja11.10941","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.5694\/mja11.10941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T17:19:30Z","timestamp":1626974370000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.5694\/mja11.10941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,9,19]]},"published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.5694\/mja11.10941"],"URL":"https:\/\/doi.org\/10.5694\/mja11.10941","archive":["Portico"],"relation":{},"ISSN":["0025-729X","1326-5377"],"issn-type":[{"value":"0025-729X","type":"print"},{"value":"1326-5377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}